However, Neff et al16 reported that SLC13A1 is not expressed in cartilage or bone and concluded that the osteochondrodysplasia that results from the deletion of SLC13A1 was secondary to the underlying metabolic disorder, which likely affects other systems, resulting in phenotypes that have yet to be described clinically. Here, SLC13A1 is linked to metabolic disease.